Cambium Bio Limited
CMB
Rank in Stocks
#32456
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Share Price
$0.31613178
Last synced: 2026-10-21
Market Cap
$9.30M
Change (1 day)
-0.39%
Change (1 year)
5,893.70%
Country
AU
Trade Cambium Bio Limited (CMB)
Category
Healthcare
Stock price history for Cambium Bio Limited (CMB)
Highest end of day price: $0.01 on 2024-05-01
Lowest end of day price: $0.25 on 2013-09-01
Lowest end of day price: $0.25 on 2013-09-01
Stock price history of Cambium Bio Limited from 2013 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2024 | 119.50% |
| 2023 | -92.08% |
| 2022 | -41.49% |
| 2021 | -42.78% |
| 2020 | 56.83% |
| 2019 | -53.42% |
| 2018 | 31.72% |
| 2017 | -21.51% |
| 2016 | 74.18% |
| 2015 | -41.39% |
| 2014 | -67.54% |
| 2013 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $534.63 | 25.37% |
US
|
|
| $211.92 | 689.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.10 | 7.61% |
NL
|
